---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-112887"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:19:40.600979+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma amends SVB credit agreement, eliminates $20M cash reserve requirement

## Summary
- Second Amendment dated Oct 2, 2024 removes $20M minimum cash requirement from SVB loan agreement.
- New covenant requires Cue to maintain at SVB lesser of $20M or 100% of consolidated cash.
- No Event of Default occurred; representations and warranties reaffirmed as of effective date.
- All other terms of the Loan and Security Agreement remain unchanged.

## SEC filing metadata
- accession: 0000950170-24-112887
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017024112887/0000950170-24-112887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017024112887/cue-20241002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-112887
- JSON: https://secwatch.observer/filing/0000950170-24-112887.json
- Plain text: https://secwatch.observer/filing/0000950170-24-112887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.